Sobi says pozdeutinurad reduced uric acid in Phase 3 gout study
Sobi said pozdeutinurad reduced uric acid levels in patients with gout in a Phase 3 study. The supplied text ends after saying Sobi will present.
Related stories
Xenia Hotels & Resorts Reports Q3 Revenue of $263.8 Million, FFO Per Share Up 56.5%
Third-quarter 2026 revenue was $263.8 million. The company reported a $2.7 million net loss attributable to common stockholders, narrower than a year earlier, while Adjusted EBITDA
M impact | EQUITY | Nov 03, 2026, 01:13 PM UTC
Yum! Brands Q3 Revenue Rises 4% to $2.05 Billion
Yum! Brands reported third-quarter 2026 diluted GAAP EPS of $5.92. EPS excluding Special Items was $1.56, compared with $1.58 a year earlier; results included a $1.68 billion pre-t
M impact | EQUITY | Nov 03, 2026, 01:13 PM UTC
Apollo Reports Q3 2026 Results, Record $114 Billion Origination
Apollo said third-quarter origination reached a record $114 billion and clients entrusted it with $270 billion in inflows over the last 12 months. It also declared a quarterly divi
M impact | EQUITY | Nov 03, 2026, 01:13 PM UTC
Chegg Cuts Q3 2026 Net Loss 73%
M impact | EQUITY | Nov 03, 2026, 01:13 PM UTC
Liberty Global Returns to Profit in Q3 2026
Liberty Global returned to profitability in Q3 2026.
M impact | EQUITY | Nov 03, 2026, 01:12 PM UTC
Sysco Reports Higher Q1 FY27 Net Profit and Revenue
Sysco reported year-over-year increases in net profit and revenue in Q1 FY27.
M impact | EQUITY | Nov 03, 2026, 01:12 PM UTC